DBCO-Doxorubicin Liposome (PEGylated) (CAT#: CLBD015LY)

Description
This formulation is Doxorubicin Liposome (PEGylated) with the dibenzocyclooctyne (DBCO) group, which can react with an azide by click chemistry. The conjugation chemistry is based on the reaction of the DBCO reagent with an azide linker to form a stable triazole. Azide moiety can be on the antibody and DBCO moiety can be on liposome and vice versa.
Lipid Composition
HSPC, Cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-DBCO
Encapsulated Drug
Doxorubicin
Buffer
Ammonium sulfate, pH 7.4
Storage
Store in dark at +4°C and do not freeze
Size
100 nm
Quantity
5mL (available in lyophilized powder)
Molecular Structure
Download
DataSheet MSDS
FAQs Published Data Customer Reviews Related Sections
  1. How is the DBCO functionality useful in these liposomes?

    The DBCO groups on these liposomes enable the use of copper-free click chemistry to conjugate azide-bearing targeting molecules, such as antibodies or peptides. This technology allows for precise targeting of the liposomes to specific cells or tissues, potentially enhancing the therapeutic efficacy of the encapsulated doxorubicin.

  2. What are the advantages of using DBCO-Doxorubicin liposomes in cancer therapy?

    These liposomes allow for targeted delivery of doxorubicin, which can lead to higher drug concentrations at the tumor site while reducing systemic exposure and toxicity. Additionally, the encapsulation in liposomes can improve the solubility and stability of doxorubicin in the bloodstream.

  3. How are DBCO-Doxorubicin liposomes prepared?

    The preparation involves mixing DBCO-functionalized lipids with doxorubicin-loaded liposomes under specific conditions that facilitate the conjugation of DBCO with azide-tagged molecules. This typically includes incubation at controlled temperatures and may involve dialysis to remove unreacted components.

  4. What should be considered when storing these liposomes?

    DBCO-Doxorubicin liposomes should be stored at 4°C and protected from light. Freezing should be avoided as it can disrupt the liposome structure and release the encapsulated drug prematurely.

  5. Can DBCO-Doxorubicin liposomes be customized for specific research needs?

    Yes, these liposomes can be tailored for different research applications by varying the type and density of azide-modified targeting molecules conjugated to the surface. This allows researchers to target different types of cells or tissues depending on the therapeutic needs.

DBCO-Doxorubicin Liposome (PEGylated)-fig1


Assessment of p700 coupling to PEGylated liposomes

This research investigates the enhanced targeting and cytotoxicity of doxorubicin encapsulated in PEGylated liposomes modified with a dibenzocyclooctyl (DBCO) functional group and linked to a TIMP3-derived peptide, p700. The modification aims to target the liposomes specifically to tumor cells, utilizing p700's affinity for multiple angiogenesis-related receptors highly expressed on tumor and vascular cells.
The experimental results demonstrated that p700-conjugated liposomes significantly improved the binding and internalization of doxorubicin in tumor cells compared to non-conjugated liposomes. In human and mouse breast cancer cell lines, the p700-conjugated complex facilitated a roughly 100-fold increase in drug uptake, resulting in heightened cytotoxic effects. This targeting strategy not only promises to enhance the efficacy of doxorubicin against tumors but also to reduce its cardiotoxic side effects by limiting systemic exposure. Overall, the use of p700 to direct the delivery of liposomal doxorubicin marks a pivotal advancement in cancer therapy, focusing on increasing the drug's tumor specificity and therapeutic index while mitigating associated risks.

Aldughaim, M. S., Muthana, M., et al. Specific targeting of PEGylated liposomal doxorubicin (Doxil®) to tumour cells using a novel TIMP3 peptide. Molecules. 2020, 26(1): 100. Under Open Access license CC BY 4.0, without modification.

  • Enhanced Targeting Precision
    Creative Biolabs' DBCO-Doxorubicin liposomes excel in targeting precision, enhancing therapeutic efficacy in tumor studies.
  • Robust Stability in Systemic Circulation
    These liposomes offer robust stability in systemic circulation, critical for our comprehensive cancer therapy research.
  • Exceptional Click Chemistry Application
    DBCO-Doxorubicin liposomes utilize click chemistry effectively, ensuring targeted delivery and minimized side effects in our studies.
  • High Encapsulation Efficiency
    The high encapsulation efficiency of these liposomes ensures maximum drug loading, which is vital for our pharmacological experiments.

Click the button below to contact us or submit your feedback about this product.

For Research Use Only. Not For Clinical Use

Online Inquiry